Celecoxib: Difference between revisions
(→Mechanism of Action: added mechanism) |
Elcatracho (talk | contribs) |
||
| Line 74: | Line 74: | ||
==See Also== | ==See Also== | ||
*[[NSAIDs]] | |||
*[[NSAID toxicity]] | |||
==References== | ==References== | ||
<Epocrates, UpToDate> | <Epocrates, UpToDate> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Latest revision as of 22:54, 7 March 2021
Administration
- Type: Nonsteroidal anti-inflammatory drugs (NSAID), COX-2 Selective
- Dosage Forms: capsule
- Dosage Strengths: 50, 100, 200, 400mg
- Routes of Administration: PO
- Common Trade Names: Celebrex
Adult Dosing
- Osteoarthritis: 200mg PO QD
- Rheumatoid arthritis: 100-200mg PO bid
- Use lowest effective dose, shortest effective treatment duration
- Consider starting at 50% of lowest dose if poor CYP2C9 metabolizer
- Ankylosing spondylitis: 200mg PO QD
- Max: 400mg/day
- Dysmenorrhea: 200mg PO bid
- Start: 400mg PO x1, may give additional 200mg on day 1 if needed
- Pain, acute: 200mg PO bid
- Start: 400mg PO x1, may give additional 200mg on day 1 if needed
Pediatric Dosing
Only for ages > 2 years old
- Juvenile idiopathic arthritis
- 10-25 kg]: 50mg PO bid
- >25 kg: 100mg PO bid
Special Populations
- Pregnancy Risk Factor:
- C (prior to 30 weeks gestation)
- D (≥30 weeks gestation)
Renal Dosing
- Avoid use in severe renal impairment
Hepatic Dosing
- Adult:Child-Pugh Class B: decrease dose 50%; Child-Pugh Class C: avoid use
Contraindications
- hypersens. to drug/class/compon.
- hypersens. to sulfonamides
- ASA or NSAID-induced asthma or urticaria
- aspirin triad
- pregnancy starting at 30 wk gestation
- CABG surgery periop use
- GI bleeding
Adverse Reactions
Serious
- GI bleeding
- GI perforation/ulcer
- MI
- stroke
- thromboembolism
Common
Pharmacology
- Half-life: 11hr
- Metabolism: CYP450
- Excretion: feces, urine
Mechanism of Action
Inhibits cyclooxygenase (COX)-2; does not affect COX-1 (at therapeutic concentrations), thereby decreasing formation of prostaglandin synthesis
Comments
See Also
References
<Epocrates, UpToDate>
